Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Interest & Investment Income (2017 - 2025)

Spero Therapeutics' Interest & Investment Income history spans 9 years, with the latest figure at $376000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 63.42% year-over-year to $376000.0; the TTM value through Dec 2025 reached $2.5 million, down 46.95%, while the annual FY2025 figure was $2.5 million, 46.95% down from the prior year.
  • Interest & Investment Income reached $376000.0 in Q4 2025 per SPRO's latest filing, down from $532000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.3 million in Q1 2024 to a low of $72000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $631850.0, with a median of $727500.0 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: surged 1237.5% in 2023, then tumbled 63.42% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $76000.0 in 2021, then skyrocketed by 840.79% to $715000.0 in 2022, then soared by 45.87% to $1.0 million in 2023, then fell by 1.44% to $1.0 million in 2024, then crashed by 63.42% to $376000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Interest & Investment Income are $376000.0 (Q4 2025), $532000.0 (Q3 2025), and $740000.0 (Q2 2025).